



Steven R. Ludwic

Jeffery T. Helw Heidi L. Kraus

ian J. Dei Buono Lynn Prengamai

DT05 Rec'd PCT/PTO

Nancy J. Leith Joseph M. Conrad III Ann E. Summerfield Helene C. Carlson Mary B. Tung Katrina Y. Pei John J. Figueroa

Admitted only in Virgin Admitted only in Texas Practice Limited to

July 24, 2002

WRITER'S DIRECT NUMBER: (202) 371-2637 **INTERNET ADDRESS:** KARENM@SKGF.COM

Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Utility Patent Application

Appl. No.09/720,086; 102(e): July 23, 2001

De Novo DNA Cytosine Methyltransferase Genes, Polypeptides and Uses Thereof

Inventors:

Li et al.

Our Ref:

0609.4560002/JAG/KRM

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Request for Corrected Official Filing Receipt;
- 2. Copy of the Official Filing Receipt with changes noted in red ink;
- Copy of the postcard stamped with the correct filing date under 35 U.S.C. 371; 3.
- Copy of the Notice of Acceptance of Application Under 35 U.S.C. 371 and 37 4. C.F.R. 1.494 or 1.495; and
- 5. One return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents July 24, 2002 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Karen R. Markowicz Agent for Applicants

Registration No. 36,351

KRM/DJN:drb Enclosures

SKGF_DC1:37596.1



IN THE UNITED STATES PATENT AND TRADEMARK OF

In re application of:

Li et al.

Appl. No. 09/720,086

102(e): July 23, 2001

For:

De Novo DNA Cytosine Methyltransferase Genes,

Polypeptides and Uses Thereof

Confirmation No. 6968

Art Unit:

Examiner: To Be Assigne

Atty. Docket: 0609.4560002/JAG/KRM

Request for Corrected Official Filing Receipt

Commissioner for Patents Washington, D.C. 20231

Attn: Office of Initial Patent Examination's Customer Service Center

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested: Filing Date should read 07/23/2001. In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red along with a copy of the stamped postcard with the correct filing date under 35 U.S.C. 371. Additionally, a copy of the Notice of Acceptance of Application Under 35 U.S.C. 371 and 37 C.F.R. 1.494 or 1.495 is enclosed which indicated incorrectly July 13, 2001 as the date on which the requirements of 35 U.S.C. 371(c)(1), (c)(2), and (c)(4) have been received. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

uerk. Marlindez

Karen R. Markowicz Agent for Applicants

Registration No. 36,351

1100 New York Avenue, N.W. Suite 600

Washington, D.C. 20005-3934

(202) 371-2600

SKGF_DC1:37599.1



Suite 600

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231

www.uspto.gov

APPLICATION NUMBER 09/720.086

FILING DATE 07/13/2004 GRP ART UNIT 1642

FIL FEE REC'D 2004

ATTY.DOCKET.NO 0609.4560002

TOT CLAIMS

IND CLAIMS 15

Sterne Kessler Goldstein & Fox

1100 New York Avenue NW Washington, DC 20005-3934

DRAWINGS

23

CONFIRMATION NO. 6968

FILING RECEIPT

OC000000006857255

Date Mailed: 10/10/2001

15

Sterme, Kessler,

GOLDSTEIN, FOX

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

En Li, Newton, MA; Masaki Okano, Malden, MA; Shaoping Xie, East Brunswick, NJ;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/14373 06/25/1999 WHICH CLAIMS BENEFIT OF 60/090,906 06/25/1998 AND CLAIMS BENEFIT OF 60/093,993 07/24/1998

Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

10/18/01

Title

De novo dna cytosine methyltransferase genes, polypeptides and uses thereof

LICENSE FOR FOREIGN FILING UNDER Title 35, United Stat s Cod , Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

Due Date: July 21, 2001 (Saturday)

Applicant: Art Unit: Li et al. To be assigned

Examiner: To be assigned

Application No.: 09/720,086 Docket: 0609.4560002 Filed:

December 20, 2000 Atty: JAG/KRM De Novo DNA Cytosine Methyltransferase Genes, Polypeptides and Uses Thereof

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

SKGF Cover Letter (in duplicate); 1.

2. PTO Fee Transmittal Form (PTO/SB/17);

Petition For Extension of Time Under 37 C.F.R. § 1.136(a)(1) (in duplicate); 3.

Copy of the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office;

5. Copy of the Notification to Comply with Requirements for Patent Applications Containing Nucle and/or Amino Acid Sequence Disclosures;

Original Declaration, executed by inventors En Li and Masaki Okano; 6.

7. Original Declaration, executed by inventor Shaoping Xie;


8. Paper and computer readable copy of Sequence Listing;

Paper and computer readable copy of Sequence Listing,
Request to Approve Proposed Drawing Corrections, along with 12 sheets of Figures hand-corrected in red in 1B-1, 1C, 2A, 2B, 2C, 3A, and 3B);

Our check no. 31978 for \$55.00 to cover the extension of time fee under 37 C.F.R. § 1.136 (small entity); and 10.

SKGF Return Postcard.

Please Date Stamp And Return To Our Courier



Date Mailed: 10/10/2001

Mm 10/18/01 NOTICE OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C 371 AND 37 CFR 1.494 OR 1.495

JAG

KRM

The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as an Elected Office (37 CFR 1.495), has determined that the above identified international application has met the requirements of 35 U.S.C. 371, and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.

The United States Application Number assigned to the application is shown above and the relevant dates are:

07/13/2001

DATE OF RECEIPT OF 35 U.S.C. 371(c)(1), (c)(2) and (c)(4) REQUIREMENTS

07/23/2001

DATE OF RECEIPT OF ALL 35 U.S.C. REQUIREMENTS

A Filing Receipt (PTO-103X) will be issued for the present application in due course. THE DATE APPEARING ON THE FILING RECEIPT AS THE "FILING DATE" IS THE DATE ON WHICH THE LAST OF THE 35 U.S.C. 371 REQUIREMENTS HAS BEEN RECEIVED IN THE OFFICE. THIS DATE IS SHOWN ABOVE. The filing date of the above identified application is the international filing date of the international application (Article 11(3) and 35 U.S.C. 363). Once the Filing Receipt has been received, send all correspondence to the Group Art Unit designated thereon.

The following items have been received:

- U.S. Basic National Fee
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

SHAKEEL AHMED Telephone: (703) 305-3659

PART 1 - ATTORNEY/APPLICANT COPY